STAT+: New biotech backed by Third Rock launches with $81 million to go after ALS, other diseases
A new biotechnology company was launched Thursday in Cambridge with $81 million in funding, joining a growing number of biotechs in the area that are based on an emerging field in cell biology.
Faze Medicines will work on “biomolecular condensates,” which it believes can be studied to develop drugs that could slow, halt, or reverse certain diseases. Condensates are membrane-less organelles, or clusters of molecules such as proteins and nucleic acids, that help cells perform vital functions.
